Please login to the form below

Chiesi

This page shows the latest Chiesi news and features for those working in and with pharma, biotech and healthcare.

Chiesi targets patient adherence via mobile app

Chiesi targets patient adherence via mobile app. Initiative will see asthma and COPD patients receive device training support. ... Patients using Chiesi’s app will be able to review their inhaler technique and can share this during their consultations

Latest news

Daily Brief: Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more

Daily Brief: Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more. ... them. UK MARKET ACCESS. NICE says no to Chiesi’s rare disease drug.
Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more

Gottlieb sets out cell and gene pathway, NICE says no to Chiesi ultra-rare treatment and more. ... them. UK MARKET ACCESS. NICE says no to Chiesi’s rare disease drug.
Chiesi's ultra-rare genetic disorder therapy wins European backing

Chiesi's ultra-rare genetic disorder therapy wins European backing. Lamzede is set to become the first approved therapy for Alpha-Mannosidosis. ... It’s the second most advanced product from Chiesi’s rare disease unit after its LSCD therapy Holoclar
AZ’s COPD triple data sets up market clash with GSK

In Europe it was pipped to the post by Chiesi, which got a green light for its Trimbow (formoterol fumarate, glycopyrronium and beclomethasone) product, but this medicine must be administered
With US approval, GSK now needs rapid uptake for COPD triple

In August, Chiesi won EU approval for its closed triple therapy Trimbow (beclometasone, formoterol and glycopyrronium), but that is administered twice-daily.

More from news
Approximately 13 fully matching, plus 29 partially matching documents found.

Latest Intelligence

The good, the bad and the ugly

GSK, AZ and Chiesi are each playing in this new market.
Deal Watch May 2016

911. The Medicines Company/ Chiesi. Product acquisition. Acquisition of cardiovascular assets Cleviprex, Kengreal and rights to Argatroban.
Anticipating the future in healthcare

The technology was licensed from the Dutch bio company uniQure BV by Chiesi, a mid-sized, family-owned pharma company based in Parma, Italy. ... Paolo Chiesi, chairman of the board of directors, and Andrea Chiesi, CEO of Chiesi Farmaceutici, are part of
Deal Watch table for September 2013

Cornerstone Therapeutics/ Chiesi Farmaceutici. Acquisition (42 per cent). US speciality pharmaceutical company focused hospital and niche respiratory products. ... 2. Global rights excluding India, Pakistan and China. 3. Acquisition of the shares not
Pharma deals during October 2012

In keeping with Chiesi's marketing capabilities, the licence is for certain countries, including Europe, Turkey and CIS countries. ... 58. † Veloxis Pharmaceuticals / Chiesi Farmaceutici. Licence. LCP-Tacro (tacrolimus) immunosuppressant for kidney

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest appointments

Akinion’s Dr Richard Jones joins Holostem Terapie Avanzate

Dr Paolo Chiesi, chairman of the board at Holostem, said: “ On behalf of the Holostem board, I am delighted to welcome Richard to the company. “

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

CAN advertising

AbbVie. ALK. Chiesi. Eisai. KIMS. LEO Pharma. Otsuka. Sanofi Pasteur MSD.
M&F Health

Alere. British Association for Sexual Health and HIV (BASHH). Chiesi. Danone.
Random42 Scientific Communication

Boston Biomedical. Boston Scientific . Bristol-Myers Squibb. BTG. Celgene. Ceva. Chiesi. Cidara Therapeutics.
Random42 Scientific Communication

Boston Biomedical. Boston Scientific . Bristol-Myers Squibb. BTG. Celgene. Ceva. Chiesi. Cidara Therapeutics.
Swordfish Advertising

Archimedes Pharma. Corporate. Chiesi. Fostair. Corporate. Clenil. Atimos. Danone. Infant feeding.